PDCD1 and hepatocellular carcinoma: Among HCC patients treated with the PD-1 inhibitors nivolumab and pembrolizumab as single agents, the incidence of rash, pruritus, and diarrhea was 10–23%, 12–19%, and 10–11%, respectively [95].